NCT02585804View on ClinicalTrials.gov

Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 24, 2017

Study Completion Date

April 24, 2017

Conditions
Focal Segmental Glomerulosclerosis
Interventions
DRUG

Dapagliflozin

Oral tablet, 10mg, PO, 8 weeks

Trial Locations (1)

M5G 2N2

Renal Physiology Laboratory, University Health Network, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

University of Toronto

OTHER

collaborator

Toronto General Hospital

OTHER

lead

University Health Network, Toronto

OTHER